Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a research note issued on Wednesday. They presently have a $98.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $137.00. Needham & Company LLC’s target price indicates a potential upside of 111.39% from the company’s current price.

ALNY has been the subject of a number of other reports. Janney Montgomery Scott started coverage on Alnylam Pharmaceuticals in a report on Wednesday, September 28th. They issued a “neutral” rating and a $74.00 price target for the company. Zacks Investment Research raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 price target for the company in a report on Tuesday, October 25th. Credit Suisse Group AG set a $145.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, September 30th. FBR & Co reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, September 8th. Finally, Piper Jaffray Cos. set a $106.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 6th. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $68.63.

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 46.36 on Wednesday. The company’s 50-day moving average price is $42.66 and its 200 day moving average price is $60.27. Alnylam Pharmaceuticals has a 1-year low of $31.38 and a 1-year high of $109.10. The firm’s market cap is $3.98 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Wednesday, November 2nd. The biopharmaceutical company reported ($1.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.14) by $0.07. Alnylam Pharmaceuticals had a negative return on equity of 33.97% and a negative net margin of 1,041.16%. The company earned $13.70 million during the quarter, compared to analyst estimates of $9.14 million. During the same period last year, the firm earned ($0.91) earnings per share. The business’s revenue was up 116.7% compared to the same quarter last year. On average, equities analysts expect that Alnylam Pharmaceuticals will post ($4.77) earnings per share for the current fiscal year.

In related news, Director David E. I. Pyott bought 27,900 shares of the firm’s stock in a transaction dated Thursday, October 13th. The stock was bought at an average price of $37.00 per share, with a total value of $1,032,300.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.00% of the company’s stock.

Several large investors have recently modified their holdings of ALNY. Vanguard Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 5,385,509 shares of the biopharmaceutical company’s stock valued at $298,843,000 after buying an additional 182,614 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Alnylam Pharmaceuticals by 0.7% in the third quarter. Price T Rowe Associates Inc. MD now owns 4,025,408 shares of the biopharmaceutical company’s stock valued at $272,842,000 after buying an additional 29,266 shares during the last quarter. Baillie Gifford & Co. increased its stake in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Baillie Gifford & Co. now owns 3,390,252 shares of the biopharmaceutical company’s stock valued at $188,125,000 after buying an additional 10,317 shares during the last quarter. Dodge & Cox bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $139,650,000. Finally, State Street Corp increased its stake in shares of Alnylam Pharmaceuticals by 13.4% in the second quarter. State Street Corp now owns 2,195,504 shares of the biopharmaceutical company’s stock valued at $121,832,000 after buying an additional 258,984 shares during the last quarter. 85.20% of the stock is owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

5 Day Chart for NASDAQ:ALNY

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.